ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.400
-0.020 (-4.74%)
At close: Dec 20, 2024, 4:00 PM
0.410
+0.010 (2.42%)
After-hours: Dec 20, 2024, 4:55 PM EST
ImmunoPrecise Antibodies Revenue
ImmunoPrecise Antibodies had revenue of 6.13M CAD in the quarter ending October 31, 2024, a decrease of -0.41%. This brings the company's revenue in the last twelve months to 24.07M, up 6.36% year-over-year. In the fiscal year ending April 30, 2024, ImmunoPrecise Antibodies had annual revenue of 24.52M with 18.65% growth.
Revenue (ttm)
24.07M CAD
Revenue Growth
+6.36%
P/S Ratio
0.62
Revenue / Employee
238,307 CAD
Employees
101
Market Cap
13.42M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2024 | 24.52M | 3.85M | 18.65% |
Apr 30, 2023 | 20.67M | 1.30M | 6.72% |
Apr 30, 2022 | 19.36M | 1.45M | 8.11% |
Apr 30, 2021 | 17.91M | 3.85M | 27.42% |
Apr 30, 2020 | 14.06M | 3.13M | 28.66% |
Apr 30, 2019 | Pro | Pro | Pro |
Apr 30, 2018 | Pro | Pro | Pro |
Apr 30, 2017 | Pro | Pro | Pro |
Apr 30, 2016 | Pro | Pro | Pro |
Apr 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Streamline Health Solutions | 18.59M |
Ekso Bionics Holdings | 17.68M |
ProPhase Labs | 12.75M |
BioXcel Therapeutics | 2.28M |
Kazia Therapeutics | 1.66M |
Innovative Eyewear | 1.56M |
GlycoMimetics | 10.00K |
IPA News
- 2 days ago - IPA to Present at The Microcap Conference 2025 - Accesswire
- 11 days ago - ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 - Business Wire
- 17 days ago - IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Business Wire
- 18 days ago - IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024 - Business Wire
- 5 weeks ago - $20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies - Business Wire
- 6 weeks ago - ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation - Business Wire
- 7 weeks ago - ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology - Business Wire